- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04588337
INtravenous TNK for Acute isChemicsTroke in China
INtravenous TNK for Acute isChemicsTroke in China (INTACT-China): a Prospective, Multi-center, Registry Study
Acute ischemic stroke is the most common type of stroke, accounting for about 60%-80% of all stroke, with high incidence, high mortality, high disability rate, has become the first cause of death in China. At present, only ultra-early thrombolytic therapy, endovascular therapy and antiplatelet therapy have obtained evidence-based medical evidence in ischemic stroke treatment, but only thrombolytic therapy and endovascular therapy can improve the good prognosis of patients. Intravenous thrombolytic therapy within 4.5 hours after the onset of ischemic stroke symptoms has been shown to be effective, which is recommended in the guidelines.
In most countries, alteplase (R-tPA) is the only drug approved for the treatment of acute ischemic stroke. Recombinant human TNK tissue-type plasminogen activator (rhTNK-tPA) is a modified recombinant tissue-type plasminogen activator, with no procoagulant effect and a longer half life. In recent years, there are some studies on the comparison of therapeutic effects of TNK-tPA and RT-PA in patients with acute ischemic stroke, and TNK shows promising especially for large artery occlussion. At present, there are few reports on the application of rhTNK-tPA in Chinese stroke patients.
The aim of this study is to evaluate the efficacy and safety of rhTNK-tPA in Chinese patients with ischemic stroke in a prospective, multicenter registration study.
Study Overview
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
-
Shenyang, China, 110016
- Recruiting
- Department of Neurology, General Hospital of Northern Theater Command
-
Contact:
- Hui-Sheng Chen, Ph.D.
- Phone Number: +86 13352452086
- Email: chszh@aliyun.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥18 ;
- The time from onset to treatment was less than 4.5 hours;
- Ischemic stroke confirmed by head CT or MRI;
- There are measurable neurological deficits;
- First onset or previous onset without obvious sequelae (Mrs ≤1 score) ;
- signed informed consent.
Exclusion Criteria:
- Severe neurologic deficits before onset (mRS ≥2) ;
- Significant head trauma or stroke in the last 3 months;
- Subarachnoid hemorrhage;
- A history of intracranial hemorrhage or head injury or acute stroke within 3 months;
- Intracranial tumors, arteriovenous malformations or aneurysms;
- Intracranial or spinal cord surgery within 3 months;
- Non-compressible arterial puncture within 7 days;
- Gastrointestinal or urinary tract hemorrhage within last 21 days;
- Major surgery within 1 month;
- Thrombocytopenia (platelet count <10×109/L);
- Use of heparin or oral anticoagulation therapy within 48 hours;
- Use of warfarin with an international normalised ratio >1.7 or PT >15 s;
- Uncontrolled hypertension (SYSTOLIC >180 mmHg OR DIASTOLIC>110 mmHg) ;
- The Blood Glucose concentration <50 mg/dl (2.7 mmol/L);
- Severe systemic disease with poor life expectancy (<3 months); ;
- Allergic to research drug;
- Within 3 months or participating in other clinical trials;
- Other conditions due to which investigators consider study participation inappropriate.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of excellent prognosis (mRS 0-1)
Time Frame: 90 ± 7 days
|
The proportion of excellent prognosis (mRS 0-1) after thrombolysis
|
90 ± 7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the proportion of good prognosis (mRS 0-2)
Time Frame: 90 ± 7 days
|
The proportion of good prognosis (mRS 0-2) after thrombolysis
|
90 ± 7 days
|
The incidence of stroke deterioration after thrombolysis
Time Frame: within 1 week
|
NIHSS score increased by more than 2, excluding cerebral hemorrhage
|
within 1 week
|
the incidence of stroke recurrence and other vascular events
Time Frame: within 90 ± 7 days
|
the incidence of stroke recurrence and other vascular events within 90 ± 7 days after thrombolysis
|
within 90 ± 7 days
|
symptomatic intracerebral hemorrhage
Time Frame: within 36 hours
|
any evidence of bleeding on the head CT scan associated with clinically significant neurological deterioration (NIHSS score ≥4 points increase)
|
within 36 hours
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- y2020-022
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke, Ischemic
-
Nordsjaellands HospitalRigshospitalet, Denmark; Metropolitan University CollegeCompletedTransient Ischemic Attack | Stroke, Ischemic | Stroke HemorrhagicDenmark
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
-
Medtronic Cardiac Rhythm and Heart FailureMedtronic Bakken Research CenterCompletedCryptogenic Symptomatic Transient Ischemic Attack | Cryptogenic Ischemic StrokeNetherlands, United States, France, Belgium, Germany, Sweden, Italy, Austria, Canada, Denmark, Finland, Greece, Slovakia, Spain
-
University Hospital, BrestCompletedStroke, Ischemic | Stroke HemorrhagicFrance
-
Umbria Bioengineering TechnologiesRecruitingStroke, Ischemic | Stroke HemorrhagicItaly
-
Sheffield Teaching Hospitals NHS Foundation TrustUnknownFatigue | Stroke, Ischemic | Stroke HemorrhagicUnited Kingdom
-
BayerRecruitingAcute Non-cardioembolic Ischemic Stroke | Prevention of Ischemic Stroke | High-risk Transient Ischemic AttackUnited States, Switzerland, Belgium, Australia, Sweden, Canada, Taiwan, Spain, Korea, Republic of, Latvia, Israel, Malaysia, China, Greece, Japan, Turkey, Netherlands, Romania, United Kingdom, Portugal, Hungary, Italy, Brazil, France, S... and more
-
University of AlbertaCompletedTransient Ischemic Attack | Minor Ischemic StrokeCanada
-
Stephanie HarrisonActive, not recruitingTransient Ischemic Attack | Stroke, IschemicUnited Kingdom
Clinical Trials on rhTNK-tPA
-
Beijing Tiantan HospitalNational Natural Science Foundation of China; Beijing Municipal Science & Technology... and other collaboratorsRecruiting
-
Xinqiao Hospital of ChongqingCSPC RECOMGEN PHARMACEUTICAL (GUANGZHOU) CO.,LTDRecruitingStroke, Ischemic | Stroke, AcuteChina
-
Beijing Tiantan HospitalRecruiting
-
The First Affiliated Hospital of University of...RecruitingIntravenous Tenecteplase Plus EVT Versus EVT Alone on 4.5 to 24 Hours After Basilar Artery OcclusionBasilar Artery Occlusion | Acute Cerebrovascular Accident | Stroke Due to Basilar Artery OcclusionChina
-
Beijing Tiantan HospitalLinyi People's HospitalActive, not recruitingThrombolysis | Ischemic Stroke, Acute | Endovascular TreatmentChina
-
Beijing Tiantan HospitalRecruitingIschemic Stroke, AcuteChina
-
Huashan HospitalShanghai 10th People's Hospital; Shanghai Fifth People's Hospital; Shanghai Deji... and other collaboratorsRecruitingIschemic StrokeChina
-
Beijing Tiantan HospitalGuangzhou Recomgen Biotech Co., Ltd.CompletedAcute Ischemic StrokeChina
-
University of MalayaUnknownTranspalatal Arch (TPA) | Oral Health Related Quality of Life (OHRQoL) | Oral Health Impact Profile Short Version 14 (OHIP 14) | Orthodontic Pain | Three Dimensional (3D) Orthodontic DeviceMalaysia
-
Children's Mercy Hospital Kansas CityWithdrawn